Not logged in Share Save
Share Save
Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma Rohlfing, Sarah; Vladimirova, Dilyana; Berger, Stephanie; Bochum, Sylvia; Otmacic, Gabrijela; Weiss, Marlene; Sipos, Bence; Biskup, Saskia; Klaumunzer, Marion; Martens, Uwe M. Share Save
Share Save
Share Save
Share Save
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT Goebell, Peter J.; Bogemann, Martin; Nusch, Arnd; Grunwald, Viktor; Muller, Lothar; Von Der Heyde, Eyck; Martens, Uwe M.; Lennartz, Carolin; Koska, Michaela; Potthoff, Karin; Kaiser-Osterhues, Anja; Grullich, Carsten; Staehler, Michael; Janicke, Martina; Marschner, Dominik Share Save
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024) Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Alguel, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V.; Kunzmann, V. Share Save
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine Latzer, Pauline; Zelba, Henning; Battke, Florian; Reinhardt, Annekathrin; Shao, Borong; Bartsch, Oliver; Rabsteyn, Armin; Harter, Johannes; Schulze, Martin; Okech, Thomas; Golf, Alexander; Kyzirakos-Feger, Christina; Kayser, Simone; Pieper, Natalia; Feldhahn, Magdalena; Wuensche, Julian; Seitz, Christian; Hadaschik, Dirk; Garbe, Claus; Hauser, Till-Karsten; la Fougere, Christian; Biskup, Dirk; Brooke, Dawn; Parker, David; Martens, Uwe M.; Illerhaus, Gerald; Blumenthal, Deborah T.; Merrell, Ryan; Lorenzo, Luisa Sanchez; Hidvegi, Mate; de Robles, Paula; Kebir, Sied; Li, William W.; Li, Vincent W.; Williams, Matthew; Miller, Alexandra M.; Kesari, Santosh; Castro, Michael; Desjardins, Annick; Ashley, David M.; Friedman, Henry S.; Wen, Patrick Y.; Neil, Elisabeth C.; Iwamoto, Fabio M.; Sipos, Bence; Geletneky, Karsten; Zender, Lars; Glas, Martin; Reardon, David A.; Biskup, Saskia Share Save
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study Kriegsmann, Katharina; Ton, Gigi Nu Hoang Quy; Awwad, Mohamed H. S.; Benner, Axel; Bertsch, Uta; Besemer, Britta; Haenel, Mathias; Fenk, Roland; Munder, Markus; Duerig, Jan; Blau, Igor W.; Huhn, Stefanie; Hose, Dirk; Jauch, Anna; Mann, Christoph; Weinhold, Niels; Scheid, Christof; Schroers, Roland; von Metzler, Ivana; Schieferdecker, Aneta; Thomalla, Joerg; Reimer, Peter; Mahlberg, Rolf; Graeven, Ullrich; Kremers, Stephan; Martens, Uwe M.; Kunz, Christian; Hensel, Manfred; Seidel-Glaetzer, Andrea; Weisel, Katja C.; Salwender, Hans J.; Mueller-Tidow, Carsten; Raab, Marc S.; Goldschmidt, Hartmut; Mai, Elias K.; Hundemer, Michael Share Save
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024) Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Alguel, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V.; Kunzmann, V. Share Save
Pelareorep plus atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study Ungerechts, G.; Arnold, D.; Goekkurt, E.; Stein, A.; Chater, J.; Martens, U. M.; Loghmani, H.; Coffey, M.; Trauger, R.; Heineman, T. C. Share Save
Pelareorep (pela) plus atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study Arnold, D.; Goekkurt, E.; Stein, A.; Martens, U. M.; Chater, J.; Ungerechts, G.; Loghmani, H.; Coffey, M.; Trauger, R.; Heineman, T. C. Share Save
Share Save
Randomized phase-III study of low-dose cytarabine and etoposide? plus ?/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia Schlenk, R. F.; Weber, D.; Krzykalla, J.; Kindler, T.; Wulf, G.; Hertenstein, B.; Salih, H. R.; Suedhoff, T.; Krauter, J.; Martens, U.; Wessendorf, S.; Runde, V.; Tischler, H. J.; Bentz, M.; Koller, E.; Heuser, M.; Thol, F.; Benner, A.; Ganser, A.; Doehner, K.; Doehner, H. Share Save
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial Doehner, Hartmut; Weber, Daniela; Krzykalla, Julia; Fiedler, Walter; Kuehn, Michael W. M.; Schroeder, Thomas; Mayer, Karin; Luebbert, Michael; Wattad, Mohammed; Goetze, Katharina; Fransecky, Lars; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Ringhoffer, Mark; Greil, Richard; Hertenstein, Bernd; Krauter, Juergen; Martens, Uwe M.; Nachbaur, David; Abu Samra, Maisun; Machherndl-Spandl, Sigrid; Basara, Nadezda; Leis, Claudia; Schrade, Anika; Kapp-Schwoerer, Silke; Cocciardi, Sibylle; Bullinger, Lars; Thol, Felicitas; Heuser, Michael; Paschka, Peter; Gaidzik, Verena I.; Saadati, Maral; Benner, Axel; Schlenk, Richard F.; Doehner, Konstanze; Ganser, Arnold Share Save
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice Martens, Uwe M.; Schroeder, Jan; Bengsch, Fee; Sellmann, Ludger; Busies, Sabine; Frank-Gleich, Stefanie; Zaiss, Matthias; Decker, Thomas; Schneeweiss, Andreas; Schuler, Martin; Grebhardt, Sina; Zacharias, Stefan; Marschner, Norbert; Kasenda, Benjamin; Potthoff, Karin; Vannier, Corinne Share Save
EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)-an open-label randomized controlled phase II study Smyth, E.; Mauer, M.; Cella, C.; Ben-Aharon, I.; Piessen, G.; Wyrwicz, L.; Al-Haidari, G.; Kanonnikoff, T. Fleitas; Boige, V.; Stahl, M.; Martens, U.; Obermannova, R.; Gomez-Martin, C.; Thuss-Patience, P.; Arrazubi, V.; Avallone, A.; Shiu, K.; Collienne, M.; Giraut, A.; Lordick, F. Share Save
Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+gastric cancer (GC) - subgroup analyses of EORTC 1203 INNOVATION, a collaboration with KCSG and DUCG Wagner, A.; Grabsch, H.; Mauer, M.; Lorenzen, S.; Bouche, O.; Thuss-Patience, P.; Elme, A.; Moehler, M.; Romario, U. Fumagalli; Kang, Y.; Folprecht, G.; Martens, U.; Guzman, M. Galan; Ducreux, M.; Garcia, M. Diez; Piessen, G.; Collienne, M.; Lordick, F. Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
